• Jacob C Jentzer, Janine Pöss, Hannah Schaubroeck, David A Morrow, Steven M Hollenberg, and Alexandre Mebazaa.
• Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
• Crit. Care Med. 2023 Sep 1; 51 (9): 122212331222-1233.

ObjectivesTo review a contemporary approach to the management of patients with cardiogenic shock (CS).Data SourcesWe reviewed salient medical literature regarding CS.Study SelectionWe included professional society scientific statements and clinical studies examining outcomes in patients with CS, with a focus on randomized clinical trials.Data ExtractionWe extracted salient study results and scientific statement recommendations regarding the management of CS.Data SynthesisProfessional society recommendations were integrated with evaluated studies.ConclusionsCS results in short-term mortality exceeding 30% despite standard therapy. While acute myocardial infarction (AMI) has been the focus of most CS research, heart failure-related CS now predominates at many centers. CS can present with a wide spectrum of shock severity, including patients who are normotensive despite ongoing hypoperfusion. The Society for Cardiovascular Angiography and Intervention Shock Classification categorizes patients with or at risk of CS according to shock severity, which predicts mortality. The CS population includes a heterogeneous mix of phenotypes defined by ventricular function, hemodynamic profile, biomarkers, and other clinical variables. Integrating the shock severity and CS phenotype with nonmodifiable risk factors for mortality can guide clinical decision-making and prognostication. Identifying and treating the cause of CS is crucial for success, including early culprit vessel revascularization for AMI. Vasopressors and inotropes titrated to restore arterial pressure and perfusion are the cornerstone of initial medical therapy for CS. Temporary mechanical circulatory support (MCS) is indicated for appropriately selected patients as a bridge to recovery, decision, durable MCS, or heart transplant. Randomized controlled trials have not demonstrated better survival with the routine use of temporary MCS in patients with CS. Accordingly, a multidisciplinary team-based approach should be used to tailor the type of hemodynamic support to each individual CS patient's needs based on shock severity, phenotype, and exit strategy.Copyright © 2023 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

41 keywords...

hide…